The TCR on αβ T cells consists of α and β chains, while γδ T cells utilize a distinct TCR structure made up of γ and δ chains, enabling them to detect a broader spectrum of antigens, without reliance on MHC [9], which allows them to target a broader range of cancer cells, including those with low mutational burdens or downregulated MHC expression. The gene discussed is HLA-C; the disease is cancer.